Equipment & Techniques
We study people with immunological illnesses of the brain, especially multiple sclerosis. Our most important work to date has been on alemtuzumab (Campath-1H), a humanised monoclonal antibody made originally in Cambridge. We started using it to treat multiple sclerosis in1991. In September 2013, alemtuzumab received its European license and in 2014 it was approved by the FDA and by NICE. Our focus now is on remyelinating therapies. We have completed our first such trial ("CCMROne") of bexarotene, publishing our results in 2021. We are completing CCMR Two , testing metformin and clemastine. And we have plans for CCMR Three. We are also doing a study of immunotherapy in people with psychosis associated with anti-neuronal antibodies. Alasdair is Deputy Head of Department for Clinical Neuroscience and also Co-Director of the Cambridge Centre for Myelin Repair.
Remyelination in multiple sclerosis
Bexarotene improves conduction in demyelinated visual pathways in multiple sclerosis [Brown, Lancet Neurology 2021]